S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

$20.95
+0.24 (+1.16 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$20.53
Now: $20.95
$21.16
50-Day Range
$11.79
MA: $18.03
$22.00
52-Week Range
$10.01
Now: $20.95
$22.28
Volume217,751 shs
Average Volume379,171 shs
Market Capitalization$702.39 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:COLL
CUSIPN/A
Phone781-713-3699

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$280.41 million
Cash Flow$2.22 per share
Book Value$2.75 per share

Profitability

Net Income$-39,130,000.00

Miscellaneous

Employees266
Market Cap$702.39 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.


Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its earnings results on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.03. The specialty pharmaceutical company had revenue of $72.94 million for the quarter, compared to analysts' expectations of $74.32 million. Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The company's revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.50) earnings per share. View Collegium Pharmaceutical's Earnings History.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Collegium Pharmaceutical.

What price target have analysts set for COLL?

6 equities research analysts have issued 12-month price targets for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $36.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 28.9% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

What is the consensus analysts' recommendation for Collegium Pharmaceutical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Has Collegium Pharmaceutical been receiving favorable news coverage?

Press coverage about COLL stock has trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Collegium Pharmaceutical.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 2,450,000 shares, a decrease of 8.2% from the October 31st total of 2,670,000 shares. Based on an average daily volume of 382,400 shares, the days-to-cover ratio is presently 6.4 days. Currently, 8.8% of the shares of the stock are sold short. View Collegium Pharmaceutical's Current Options Chain.

Who are some of Collegium Pharmaceutical's key competitors?

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Celgene (CELG), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), Bausch Health Companies (BHC) and GW Pharmaceuticals PLC- (GWPH).

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:
  • Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 55)
  • Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)
  • Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)
  • Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 35)

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (3.63%), State Street Corp (2.08%), Massachusetts Financial Services Co. MA (1.75%), Squarepoint Ops LLC (0.25%), Alberta Investment Management Corp (0.17%) and Strs Ohio (0.16%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

Which major investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Rice Hall James & Associates LLC, Teton Advisors Inc., State of Tennessee Treasury Department, NBW Capital LLC and Massachusetts Financial Services Co. MA. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was acquired by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, State Street Corp, Alberta Investment Management Corp, Creative Planning, Janney Montgomery Scott LLC, Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Collegium Pharmaceutical.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $20.95.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $702.39 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.


MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  293 (Vote Underperform)
Total Votes:  583
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel